| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Medical Research Council Group in Molecular Endocrinology, CHUL Research Center, Laval University Medical Centre, Quebec, G1V 4G2 Canada
Mouse C127 cells, transfected with the chicken calmodulin (CaM) gene and overexpressing CaM protein, were used to evaluate the effect of elevated levels of CaM on the sensitivity of these cells to various anticancer drugs. Clones C2 and C3 overexpress CaM mRNA by 40- and 80-fold, respectively, and CaM protein 3- and 8-fold, respectively. These cell lines were tested for their sensitivity to vincristine, vinblastine, bleomycin, and Adriamycin by comparing the 50% inhibitory concentration in a 72-h growth inhibition assay. The 50% inhibitory concentration values for vincristine with C2 and C3 cells were 6.27 ± 0.56 nM and 6.60 ± 0.96 nM, respectively. These values were significantly lower than 13.9 ± 0.79 nM for the parental C127 cells and 14.0 ± 1.55 nM for clone 6.8 (the control cell line for transfection without the chicken CaM gene) at P
0.005. The proliferation of C2 and C3 cells was inhibited at lower concentrations of vinblastine as well. The 50% inhibitory concentration values for the C2 and C3 cell lines were approximately one-half those required for C127 or clone 6.8 cells. However, no significant difference in the sensitivity to the DNA-binding drugs, bleomycin and Adriamycin, was observed between the different cell lines. The uptake of [3H]vinblastine was evaluated and found to be increased 1.6- and 2.8-fold in C2 and C3 cells, respectively, as compared with that value obtained for C127 cells. Moreover, the efflux of [3H]vinblastine from vinblastine-loaded cells was also observed to be decreased in the C2 and C3 cell lines. These data suggest that the increase in CaM expression in the C2 and C3 cell lines might be related to the higher sensitivity of these cells to Vinca alkaloids. This increased sensitivity appears to be due to the increase in intracellular concentration of the Vinca alkaloids as a result of an increase in drug uptake and a decrease in efflux. Moreover, the increased sensitivity of clones C2 and C3 to Vinca alkaloids appears to be specific to this class of drugs in that no collateral effects were observed for the DNA-damaging drugs, Adriamycin and bleomycin.
1 Present address: Department of Pediatrics, M1E University School of Medicine, 2-174 Edobashi Teucity, Mie, 514 Japan.
2 Supported by Developmental Grant NO DG-319 from the Medical Research Council of Canada. Present Address: Department of Biochemistry, Bio-Mega Inc., 2100, rue Cunard, Laval (Quebec), H7S 2G5 Canada.
3 Supported by a Group Grant for Molecular Endocrinology from the Medical Research Council of Canada. To whom requests for reprints should be addressed, at Department of Biochemistry, Bio-Mega Inc., 2100, rue Cunard, Laval (Quebec), H7S 2G5 Canada.
Received 9/26/88. Accepted 7/16/90.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |